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Abstract A simple, rapid, sensitive, cost effective and reproducible reverse 
phase high performance liquid chromatographic (RP-HPLC) method was 
developed and validated for the stability testing of rufinamide. The proposed 
RP-HPLC method was developed on phenome-nex LunaR C-18 5µm ,250 mm 
× 4.6 mm id. Column (at ambient temperature) and mobile phase consisting 
of phosphate buffer: acetonitrile (60:40) was delivered at a flow rate 1.0ml/
min. The analyte was detected by using UV detector at the wavelength of 293 
nm. The method was found to be linear over the concentration range of 50-
150 µgml-1 (r2=0.999). 30. The retention time of rufinamide was 4.717 min.
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1. intRoDuCtion
Stability testing forms an important part in the process of drug product development. Active pharmaceutical ingredient (API) is the important part of drug formulation and drug degrades with time so there is a need 
to develop methods which can detect degradation as well as degraded products 
(Chafez, L., 1971 and Sethi, P.D., 2001). The purpose of stability testing is to 
provide evidence on how the quality of drug substance varies with time under 
the influence of variety of environmental factors such as temperature, humidity 
and light which enables recommendation of storage conditions, retest periods 
and shelf life. 
1.1 Drug Profile (Rufinamide) 
Description: (1-[(2, 6-difluorophenyl)methyl]triazole-4-carboxamide)
Rufinamide is an anti-epileptic is an structural analogue of MK801, 
carbamazepine and valproic acid recent analogue to gabapentin.












Physical state White crystalline powder
Melting point 237 - 2400 C
Solubility in Water Very low Soluble in water and soluble in THF and methanol
Stability Stable under ordinary conditions.
Assay 98.5%
Residue on Ignition 0.15% max
Loss on  Drying 9.5-12.5% max
Optical Rotation -0.820 
Heavy Metal ≥ 20 ppm
Category Anti-epileptic Drug  
State Solid
Half Life 6-10 hours
1.2 Method Development
Number of methods are available to carryout stability indicating assay e.g. 
gas chromatography and nuclear magnetic resonance (NMR) (Chatwal, G., 
Anand, S.K., 2004 and Riley, M., Rosanke, T.W., 1996). High performance 
liquid chromatography (HPLC) is supposed to be the most efficient because it 
utilizes columns packed with very smaller particles and higher flow rate, which 
provides improved resolution, speed and sensitivity. Additional advantage of 
HPLC is that stability indicating assay of drugs can be carried out effectively 
in a short time (Boubakar, B.B., Etienne, R., et al., 2001; Hong, D., Shah, M., 
2000 and Kar, A., 2005).










The HPLC system consisted of HPLC 10AT-VP (Shimdadzu corporation ltd., 
Kyoto, Japan), manual injector port with 20 µL fixed loop (Rheodyme USA), 
UV detector SPD-20A (Shimadzu Corporation Ltd., Kyoto, Japan) and LC-
20 AT (Prominenceseries) pumps were used. Separation was carried out on 
phenomenax C18, column (250 mm × 4.6 mm, 5 µm) Japan. Detector output 
was quantified on Spinchrom CFR chromatography software. Mettler-Toledo 
International Inc. Greifensee (Switzerland) microbalance was used for the 
purpose of weighing, and spinix vortex was used for the mixing. Samples were 
injected into HPLC system using Hamilton micro syringe.
2.2 Chemicals and Reagents
A gift sample of pure rufinamide was supplied from Varda Biotech pvt. Limited, 
Mumbai. Acetonitrile, water, methanol, potassium dihydrogen phosphate and 
triethylamine were procured from M/S Qualigens Fine Chemicals, Mumbai.
2.3 Methods
2.3.1 Selection of wavelength
10 ppm of drug solution was prepared by dissolving 100 mg of drug in small 
amount of methanol and volume was adjusted to 100 mL; after that 1 ml of 
above solution was diluted to 100 mL with methanol to get final concentration 
of 10 ppm. The solution was scanned in the U.V range of 200 nm to 400 nm 
(Green, J.M., 1996).
2.3.2 Preparation of Mobile Phase
For the analysis of rufinamide the aqueous system selected was phosphate 
buffer. Dissolved 6.08 Gm of potassium dihydrogen phosphate in sufficient 
water to produce 1000mL. pH was adjusted with glacial acetic acid using 
pH meter. After that buffer was mixed and sonicated with organic solvent i.e. 
acetonitrile in the ratio of 60 : 40 (Taylor and Francis, 2007).
2.3.3 Preparation of Calibration Curve
Stock solution (50 µgmL-1) of rufinamide was prepared by dissolving in mobile 
phase. The stock solution of rufinamide was further diluted with mobile phase 








to give the series of standard dilution for preparation of calibration curve 
(Taylor and Francis., 2007). The different concentration of sample solution 
(12.5, 25, 50, 62.5, 75, 100 µgml-1) was injected in the concentration range of 
50% - 150% of drug substanceand the Calibration Curve results are presented 
in Table 1 and Figure 1.
table 1: Linearity data for Rufinamide
S.no. Concentration/µgml-1 inj-1/Area inj-2/Area inj-3 Area
Average area 
count/mV*sec
1 12.5 336 338 340 338
2 25 668 662 674 668
3 50 1368 1333 1340 1337
4 62.5 1680 1696 1703 1693
5 75 1998 2009 2008 2005




Figure 1. Linear calibration curve of rufinamide ( Area vs Concentration / µg/ml-1)
2.3.4 Preparation of standard solution and test solution
Standard and test stock solutions (50 ppm) of rufinamide were prepared using 
100 mg of standard and test sample of rufinamide. Drugs was dissolved in 25 
mL sof methanol and sonicated for 10 min. Then the volume was made up to 
100 mL with diluent. After that 5mL of above solution was diluted up to 100 
mL with methanol. 








Optimisation of chromatographic conditions
The mobile phase for the proposed method (Phosphate buffer pH 4 : 
Acetonitrile 60 : 40) was filtered through 0.45 µm membrane filter. It was 
degassed with a sonicator for 15 min and pumped from the reservoir to the 
column (Phenomenex C-18, 250 mm × 4.6 mm, 5µm) at aflow rate of 1mL 
Standard
Figure 2 Figure 3
Figure 4 Figure 5
Sample Chromatogram
Figure 6 Figure 7
Figure 8 Figure 9








min-1. The run time was set at 10 min. Prior to injection of the drug solutions 
the column was equilibrated for at least 1 h with mobile phase flowing through 
the system.The analyte was monitored at 225 nm and data acquired was stored 
and analyzed with spinchrom CFR chromatography software.
2.4 Method Validation Studies
Selectivity of the method was assessed on the basis of elution of Rufinamide 
using the above mentioned chromatographic conditions. The linearity, 
precision, accuracy, limit of detection, limit of quantitation and robustness has 
been validated for the determination of Rufinamide.
2.4.1 System precision
Six replicate injections of standard solution were given and mean of all of 
these values gives rise to the RSD value obtained. According to USP %RSD 
(Relative Standard Deviation) should not be more than 2% (Riley, M., Rosanke, 
T.W., 1996).
2.4.2 Method Precision
Method precision or Intra-assay precision data were obtained by repeatedly 
analyzing, in onelaboratory on one day, aliquots of homogeneous sample, each 
of which were independently prepared according to method procedure (Sethi, 
P.D., 2001 and Kar, A., 2005).
2.4.3 Linearity
Linearity of method is determined in the range 50-150 µg mL-1 (50%-150%). 
According to International Conference on Harmonisation (I.C.H) guidelines 
correlation coefficient should be less than 0.999 (ICH, 1996).
2.4.4 Ruggedness
This analysis was repeated with different column on different day with different 
analyst and different system and %RSD value was determined.
2.5 Stability in Analytical Solution
A drug solution of 50 ppm was prepared and kept at room temperature i.e. 
25oC for 24 hrs. After that drug solution was analyzed and it was found to be 
stable at room temperature (Chafez, L., 1971).
2.5.1 Degradation studies of Rufinamide
The drug was allowed to degrade in acidic, basic, oxidative and thermal 
conditions (Chafez, L., 1971).
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3. ReSultS AnD DiSCuSSion
3.1 System precision
The system precision was analyzed by six replicate injections each of standard 
solutions of rufinamide (50 ppm) into the HPLC system and the results are 
presented in Table 2. Percentage RSD for system precision was found to be 
0.75%.
table 2: Different trials carried out for developing the current HPLC
S. 
no




lunaR C18 (4.6 × 
250) mm, 5µm
Ammonium acetate 
(pH-6.7) : Can (60 
: 40)





lunaR C18 (4.6 × 
250) mm, 5µm
Ammonium acetate 
(pH-6.7) : Can (55 
: 45)
Isocratic 20µl Peak shape 





lunaR C18 (4.6 × 
250) mm, 5µm
Ammonium acetate 
(pH-2.5) : ACN : 
Methanol 
 (60 : 30 : 10)
Isocratic 20µl Peak width was 
more (peak 





lunaR C18 (4.6 × 
250) mm, 5µm
Triethylamine 
(pH-3) : ACN 
 (70 : 30)






lunaR C18 (4.6 × 
250) mm, 5µm
Triethylamine 
(pH-3) : ACN 
 (50 : 50)







lunaR C18 (4.6 × 
250) mm, 5µm
Triethylamine 
(pH-3) : Methanol 
(80 : 20)
Isocratic 20µl More run time, 





lunaR C18 (4.6 × 
250) mm, 5µm
Triethylamine 
(pH-4) : Methanol 
(75 : 25)
















) (pH-4) : 
ACN (50 : 50)
















) (pH-4) : 
ACN (60 : 40)

















) (pH-4) : 
ACN (60 : 40)














Two injections of standard solutions of rufinamide (50 ppm) were injected 
to check the system suitability. Then six sample rufinamide each batch were 
prepared separately andinjected in duplicate. Results are presented in Table 3, 
then %RSD for method precision was found to be 0.77%.












Linearity was determined by injecting six replicate injections of standard 
solutions of rufinamide (50 ppm) to check the system suitability. Then, the 
different concentration of sample solution was injected in duplicate in the 
concentration range of 50%–150% of drug substance, and the results are 
presented in Table 3. The correlation coefficient was found to be 0.999 from 
six replicate injections.
3.4 Ruggedness
Analysis was carried out with different analyst, using different column and 
different day and the results are presented in Table 4. The %RSD for ruggedness 
was found to be 0.44%.
3.5 Robustness
Robustness is the capacity of a method to remain unaffected by small 
deliberate variations in method parameters. Such as change in flow rate (± 
10%), pH (± 0.2 units) and organic content (± 2%). The results are presented 
in Table 6.9- Table 6.17. along with system suitability parameters of normal 
methodology.
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Standard 50.16 1324 1342 1333
Sample 1 50.16 1338 1348 1343 99.82
Sample 2 50.02 1340 1336 1338 99.72
Sample 3 50.85 1346 1339 1343 98.46
Sample 4 50.16 1340 1364 1352 100.49
Sample 5 50.12 1350 1346 1348 100.27





Figure 10 Figure 11
Standard
Figure 12 Figure 13
Sample Chromatogram








Figure 14 Figure 15
Figure 16 Figure 17











Standard 50.26 1358 1372 1365 99.87
Sample 1 50.06 1359 1368 1368 99.98
Sample 2 50.02 1358 1362 1362 99.77
Sample 3 50.04 1363 1367 1367 99.14
Sample 4 50.03 1348 1359 1359 99.31
Sample 5 50.06 1352 1366 1366 99.61





3.6 Stability in Analytical Solution
The sample was found to be stable at 25ºC for 24 hrs and the overall %RSD 
was found to be 0.45 and the result are presented in Table 7.
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3.7 Degradation studies of Rufinamide
The drug was allowed to degrade in acidic, basic, oxidative and thermal 
conditions and results are presented in Table 8. There was no co eluting peaks 
(Figure 18).
4. ReSultS
Figure 2 shows typical chromatogram of Rufinamide. System stability tests 
were carried out on freshly prepared standard stock solutions of Rufinamide at 
25°C (Table 5). The calibration curve was linear in the range of 50-150 µg/ml 
for rufinamide. The degradation studies of Rufinamide are shown in Table 6.
table 6: Robustness parameter
Parameter % RSD %Assay
Increased Wavelength (+5) 0.74 98.88
Decreased Wavelength (-5) 0.64 98.86
Increased  pH (- 0.2) 0.69 99.38
Decreased pH (+ 0.2) 0..69 99.65
Increased  Flow rate (+0.1ml) 0.84 98.79
Decreased Flow rate (-0.1ml) 0.77 99.59
Organic content increased 0.66 99.58
Organic content decreased 0.71 99.19
table 7: Stability data for Rufinamide (at 25°C):










1 6/8/2010 14:00 1338 0.11 99.55
2 6/8/2010 14:30 0 : 30 : 00 30 1340 0.15 99.70
3 6/8/20103:00:00 
PM
1 : 00 : 00 60 1336 0.46 99.41
4 6/8/2010 17:00 3 : 00 : 00 180 1350 0.61 100.45
5 6/8/2010 20:00 6 : 00 : 00 360 1355 0.69 100.82
6 6/9/2010 8:00 18 : 00 : 00 1080 1330 0.69 98.96












Figure 18. Chromatogram of Rufinamide. (The peak retention time of Rufinamide 
was 4.717 min)
table 8: Degradation studies of Rufinamide:
Degradation studies % degradation
Alkaline degradation (0.05 N NaOH, 1 h) 3
Alkaline degradation (0.01 N NaOH, 1 h) 7
Alkaline degradation ( 1 N NaOH, 1 h) 13
Alkaline degradation ( 2 N NaOH, 1 h) 15
Alkaline degradation (5 N NaOH, 1 h) 25
Acidic degradation ( 0.1 N HCl) 16










Thermal degradation ( solid sample, 100 °C, 24 h) 0
Thermal degradation ( solid sample, 100 °C, 24 h) 0
5. ConCluSion
HPLC method was successfully developed and validated for determination of 
rufinamide. The total run time was 10 min. Method validation results have 
proved the method to be selective, precise, accurate, robust and stability 
indicating. Thus, the developed stability indicating assay method can be 
successfully applied for routine analysis of rufinamide.
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